文献速递类风湿关节炎

类风湿关节炎中与不同先进疗法联用的最佳传统合成改善病情抗风湿药:系统文献综述与Meta分析

Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该系统综述与Meta分析旨在比较甲氨蝶呤(MTX)与非MTX传统合成改善病情抗风湿药(csDMARDs)联合先进疗法(生物制剂和靶向合成DMARDs)在类风湿关节炎中的安全性和有效性。共纳入41项研究进行系统综述,21项进行Meta分析。结果显示,非MTX csDMARDs联合TNFi时6个月EULAR应答率低于MTX(RR 0.93,95%CI 0.87-1.0,P=0.04),12个月保留率也较低;联合阿巴西普时两组有效性和安全性相似;联合利妥昔单抗时来氟米特EULAR良好应答率高于MTX(RR 1.38,95%CI 1.13-1.68,P=0.001),不良事件率相似。托珠单抗或JAK抑制剂无法进行Meta分析。结论认为不同csDMARDs联合先进疗法在RA中安全有效,MTX联合TNFi略优,而来氟米特联合利妥昔单抗可能优于MTX。

要点

  • 非MTX csDMARDs联合TNFi的6个月EULAR应答和12个月保留率低于MTX。
  • 来氟米特联合利妥昔单抗的EULAR良好应答率高于MTX,不良事件率相似。
  • 阿巴西普联合MTX或非MTX csDMARDs的有效性和安全性相似。

核心结论

  • 不同csDMARDs联合先进疗法在RA患者中似乎安全有效。
  • MTX联合TNFi似乎略优于其他csDMARDs。
  • 来氟米特联合利妥昔单抗可能优于MTX。

研究设计与样本

  • 系统文献检索比较MTX与非MTX csDMARDs(来氟米特或其他)联合TNFi、阿巴西普、利妥昔单抗、托珠单抗和JAK抑制剂的疗效、保留率和安全性。
  • 共检索3842篇文章,41项研究纳入系统综述,21项纳入Meta分析(TNFi 13项、阿巴西普3项、利妥昔单抗5项)。
  • Meta分析使用RevMan软件,采用逆方差法,固定或随机效应模型,估计风险比(RR)和95%置信区间(95%CI)。

主要发现

  • TNFi联合非MTX csDMARDs组6个月EULAR应答率低于MTX组(RR 0.93 [95% CI 0.87, 1.0],P=0.04;n=3843;I2=28%),12个月保留率也较低。
  • 阿巴西普联合MTX或非MTX csDMARDs的有效性和安全性相似。
  • 利妥昔单抗联合来氟米特组EULAR良好应答率高于MTX组(RR 1.38 [95% CI 1.13, 1.68],P=0.001;n=2078;I2=0%),不良事件率相似。
  • 托珠单抗或JAK抑制剂的Meta分析无法进行。

关键数值与推荐

  • TNFi联合非MTX csDMARDs vs MTX:6个月EULAR应答RR 0.93(95%CI 0.87-1.0),P=0.04,n=3843,I2=28%。
  • 利妥昔单抗联合来氟米特 vs MTX:EULAR良好应答RR 1.38(95%CI 1.13-1.68),P=0.001,n=2078,I2=0%。

临床怎么用

  • 当MTX不能使用时,非MTX csDMARDs联合先进疗法是安全有效的选择。
  • 联合TNFi时MTX可能略优于其他csDMARDs,但差异较小。
  • 联合利妥昔单抗时来氟米特可能优于MTX。

局限性

  • 托珠单抗或JAK抑制剂的Meta分析无法进行。
  • 纳入研究间存在异质性(TNFi分析I2=28%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In rheumatoid arthritis, the association between advanced therapies (including biologic disease-modifying antirheumatic drugs [DMARDs] and targeted synthetic DMARDs) and methotrexate (MTX) is recommended by international societies. When MTX cannot be used, other conventional synthetic DMARDs (csDMARDs) may be proposed. We aimed to compare the safety and efficacy of MTX and non-MTX csDMARDs in combination with advanced therapies. METHODS: We systematically searched the literature for studies comparing the effectiveness, retention rate, and safety of MTX versus non-MTX csDMARDs (leflunomide or others) in combination with tumor necrosis factor inhibitors (TNFi), abatacept, rituximab, tocilizumab, and JAK inhibitors. Meta-analysis was performed with RevMan, using an inverse variance approach with fixed or random-effects models. Risk ratios (RRs) and 95% confidence intervals (95% CIs) were estimated. RESULTS: The literature search revealed 3,842 articles; 41 studies were included for the systematic literature review and 21 for the meta-analysis: 13 with TNFi, 3 with abatacept, and 5 with rituximab. For TNFi, the European Alliance of Associations for Rheumatology (EULAR) response at 6 months was lower for patients receiving non-MTX csDMARDs than for those using MTX (RR 0.93 [95% CI 0.87, 1.0], P = 0.04; n = 3,843; I2 = 28%), with a lower retention rate at 12 months. For abatacept, effectiveness and safety were similar between the 2 groups. For rituximab, a good EULAR response was higher with leflunomide than MTX (RR 1.38 [95% CI 1.13, 1.68], P = 0.001; n = 2,078; I2 = 0%), with similar adverse event rates. Meta-analysis for tocilizumab or JAK inhibitors could not be performed. CONCLUSION: The different csDMARDs seem safe and efficient to combine with advanced therapies in RA patients. Although MTX seems slightly superior to other csDMARDs in combination with TNFi, leflunomide might be superior to MTX in combination with rituximab.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Decarriere G, Barnetche T, Combe B, et al. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021. PMID: 32216091. doi:10.1002/acr.24195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。